Atelerix Life Sciences

Current Approach

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Current Approaches Fall Short

[/vc_column_text][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

FDA-approved opioid receptor antagonists such as Naloxone can reverse the most serious life-threatening opioid-induced side effects, but they:

[/vc_column_text][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

  • Also reverse the pain relief, leaving patients in agony
  • Are short-acting, requiring continuous re-administration
  • Are only weakly effective against synthetic opioids like fentanyl
  • Do nothing to modulate addiction

[/vc_column_text][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Most ongoing research to minimize side effects is focused on direct targeting of opioid receptors – these efforts have largely not been successful.

[/vc_column_text][/vc_column][/vc_row]